Biswadev Mitra a, Mark Fitzgerald a, Peter A Cameron a, Russell L Gruen a. The Lancet, Volume 376, Issue 9746, Page 1049 - 1050, 25 September 2010
The CRASH-2 trial (July 3, p 23)1 showed reduced trauma mortality through the simple and cheap intervention of tranexamic acid, placing it into a growing list of options for managing the acute coagulopathy of trauma.

This list includes fresh frozen plasma, cryoprecipitate, platelets, fibrinogen, thrombin, prothrombin complexes, recombinant factor VIIa, and now tranexamic acid—all with varied levels of efficacy, but uncertain effectiveness.

Weblink here